Suven Life Sciences has received two patents viz., US7,718,690 and US 7,781,476 for its New Chemical Entities (NCEs) from US Patent Office for the treatment of disorders associated with neurodegenerative diseases and these patents are valid until 2022.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and schizophrenia.

With these new patents, Suven has total of 8 granted US patents on NCEs. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.

Venkat Jasti, CEO, said, "We are very pleased by the grant of these patents to Suven by US Patent Office for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $30 billion market potential globally"

The company has 12 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and schizophrenia.